Rentschler Biopharma Capabilities Update July 2026: Large Molecule

At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing. As a 100% dedicated biologics CDMO, we combine more than 50 years of proven biologics expertise with deep technical knowledge, regulatory insight, flexible cGMP manufacturing, and dedicated program management to support each molecule’s unique path to market.

We build partnerships rooted in trust, transparency, and long-term commitment, helping clients move forward with confidence at every stage of development. As a fifth-generation, family-owned company focused exclusively on our clients’ projects, we offer the reliability, agility, and scientific excellence needed to bring innovative, life-changing biopharmaceuticals to patients worldwide.

A key part of this offering is our Milford, Massachusetts site, which expands our U.S.-based clinical and commercial manufacturing capabilities and strengthens our ability to support clients from early development through commercialization.